Chiasma Looks Ahead To First Approval With "Revolutionary" Technology Opportunity

Anticipating an April 15 user fee date for oral ocreotide for acromegaly, Chiasma thinks its platform technology to make peptides orally available can offer substantial opportunities for therapeutic optionality.